KR101272606B1 - Yeast hydrolysate having appetite suppression, weight-loss, and fat accumulation inhibition, food containing it, and preparation method thereof - Google Patents

Abstract

PURPOSE: A food and an appetite suppressing composite are provided to include hydrolysate which treats yeast with transgultaminase. CONSTITUTION: A food composition for appetite suppressing composite comprises yeast hydrolysate as an active ingredient. Transglutaminase is manufactured by hydrolysating flavourzyme after hydrolysating yeast to flavourzyme. The yeast is Saccharomyces cerevisiae. The yeast hydrolysate increases the ability of leptin secretion, promoting the ability of cocaine, and amphetamine, related transcript expression, and induces the suppression of appetite and the reduction of the amount of food intake. [Reference numerals] (AA) Weight increase amount; (BB) Comparison group; (CC) Comparative example 1; (DD) Comparative example 2; (EE) Example 1

Description

YEAST HYDROLYSATE HAVING APPETITE SUPPRESSION, WEIGHT-LOSS, AND FAT ACCUMULATION INHIBITION, FOOD CONTAINING IT, AND PREPARATION METHOD THEREOF}

The present invention relates to a food comprising yeast hydrolyzate.

The incidence of metabolic syndrome, diabetes mellitus, and cardiovascular disease following obesity continues to increase regardless of race, gender, and age (Yun Sung-duk, Kyung-yul Jung, Sa-yeop Kim, and Woo-kwang Chun. (2010). , Impact on basic fitness, 1RM and isokinetic muscle function, Journal of Korean Developmental Development, 18 (3): 179-185). The prevalence of obesity in Korea increased by 25.7% in 1998 and 31.7% in 2007 to 5.7% over 10 years based on a body mass index of 25%. This trend is clear in men, which is lower than the US 34.3% and higher than Japan's 24.0%. (Gang, Eun-Jung. (2010) Comparison of Health Levels in Korea with OECD Countries. Health and Welfare Forum, 167: 104-112.) An epidemiologic study of Koreans reported that an increase in BMI was associated with an increase in mortality and a high incidence of atherosclerosis and cardiovascular disease (Lee. (2011). , Cardiovascular Risk Factors and Their Effects on Insulin Resistance, Journal of Korean Developmental Development, 19 (1): 25-31).

Recently, many studies have been reported, along with interest in dietary composition and nutrients for the prevention and treatment of obesity and weight control. Among them, energy restricted diet, one of the widely used methods for weight control, has been reported to reduce the satiety and promote the appetite so that it is difficult to continue the diet. DE, Wing R, Buonocore C, Sturis J, Polonsky D, Fitzsimmons M. (1993) Relative effects of calorie restriction and weight loss in non insulin-dependent diabetes melitus.J Clin Endocrinol Metab 77: 1287-1293.).

On the other hand, signals from the long-term and short-term food intake control from the peripheral acts on the central nervous system to regulate eating behavior. The main site involved in this is the hypothalamus, especially the dorsal vagal complex of the arcuate nucleus and the brain stem (Schwartz MW, Woods SC, Porte D, Jr., Seeley RJ, Baskin DG. (2000) Central nervous system control of food intake, Nature 404: 661-671). The hypothalamus is a relatively free area of contact with blood factors due to the incomplete blood-brain barrier (BBB) and also receives signals from other parts of the brain. The hypothalamus integrates peripheral and central signals to regulate homeostasis regarding food intake, physical activity, and basic energy consumption.

The hypothalamus is a region of the brain that plays an important role in dietary control. Arcuate nucleus, paraventricular nucleus, ventromedial hypothalamic nucleus, perifornical area, and lateral hypothalamic area in the hypothalamus are involved in dietary intake. It is known to be involved (Seeley & Woods, 2003). In particular, the hypothalamus of the arch of the hypothalamus leptin (leptin) and insulin (insulin) and other hormones act to centrally regulate dietary intake. In the nucleus, there are two types of neurons that express leptin receptors and are sensitive to hormones, one that expresses neuropeptide Y (NPY) and Agouti-related protein (AgRP), and the other type pro-opiomelanocortin. (POMC) and neurons expressing cocaine- and amphetamine-related transcript (CART) (Morton et al., 2006). The two groups of neurons regulate diet in the opposite direction to hormone signals input from the periphery, where NPY / AgRP-expressing neurons increase dietary intake, while POMC-expressing neurons inhibit dietary intake. Is involved in dietary intake (Schwartz MW, Porte Jr D. (2005) Diabetes, obesity, and the brain.Science 307: 375-379).

On the other hand, NPY (neuropeptide Y) is a neurotransmitter that affects energy homeostasis, in which the neuronal cell bodies in the hypothalamus arcuate nucleus (ARC) exist, and the axons extend into the paraventricular nucleus (PVN). O'Donohue TL, Chronwall BM, Pruss RM, Mezey EZ, Eiden LE, Massari VI, Tessel RE, Pickel VM, DiMaggio, DA, Hotchkiss AJ, Crowley WR, Grojec ZZ. (1985) Neuropeptide Y and peptide YY neuronal and endocrine systems.Peptides 6 (4): 755-768). NPY release increases appetite and reduces brown fat thermogenesis, while leptin inhibits the release of NPY from the hypothalamus, resulting in a decrease in fat tissue (Stephens TW, Basinski M, Bristow PK, Bue-Valleskey JM, Burgett SG, Crft L, Hale J, Hoffmarm J, Hsiung HM, Kriauciunas A, MacKellar W, Rosteck Jr PR, Schoner B, Smith D, Tinsley FC, Zhang XY, Heinlan M. (1995) The role of neuropeptide Y in the antiobesity action of the obese gene product.Nature, 377 (6549): 530-532). CART promotes metabolism, suppresses appetite and increases insulin secretion, allowing energy to be used in muscle cells rather than accumulating fat.

Existing energy restriction diet (energy restricted diet) is recommended to improve obesity, but calorie restriction diet has a problem that it is difficult to continue the calorie restriction diet by reducing satiety and promoting appetite (appetite). Therefore, the development of new materials containing appetite suppression function is essential for effective obesity improvement.

The present inventors, while studying the yeast hydrolyzate, found that yeast hydrolyzate prepared by complex hydrolysis of yeast with specific enzymes regulates appetite by regulating hormones and neurotransmitters related to appetite and completed the present invention. It was.

It is an object of the present invention to provide foods with improved organoleptics.

It is also an object of the present invention to provide a composition for suppressing appetite.

In order to achieve the above object, the present invention provides a food and appetite suppressing composition comprising a hydrolyzate treated with yeast transglutaminase.

The composition comprising a hydrolyzate treated with the yeast of the present invention with a transglutaminase has the effect of suppressing appetite by controlling appetite-related hormones and neurotransmitters.

1 shows the cumulative dietary intake of ICR mice following administration of yeast hydrolysates.
2 shows leptin and ghrelin levels in blood following yeast hydrolyzate administration.
Figure 3 shows the change in the average dietary intake with long-term administration of yeast hydrolyzate.
Figure 4 shows the change in weight gain with long-term administration of yeast hydrolyzate.
Figure 5 shows the expression changes of appetite promoter protein (NPY) and appetite suppressing protein (CART) according to the long-term administration of yeast hydrolyzate.

The present invention relates to a composition for inhibiting appetite comprising a yeast hydrolyzate as an active ingredient.

In another aspect, the present invention comprises a yeast hydrolyzate as an active ingredient, and relates to any one prophylactic and therapeutic pharmaceutical composition selected from the group consisting of atherosclerosis, visceral obesity, abdominal obesity, hyperlipidemia, fatty liver and obesity.

The present invention also comprises the steps of hydrolyzing the yeast; And

It relates to a method for producing an appetite suppressing composition comprising the step of obtaining the yeast hydrolyzate.

In another aspect, the present invention comprises the steps of hydrolyzing the yeast to flavozyme;

Hydrolyzing the yeast flavozyme hydrolyzate with transglutaminase; and

Atherosclerosis, visceral obesity, abdominal obesity, hyperlipidemia, fatty liver and obesity comprising the step of obtaining the yeast transglutaminase hydrolyzate comprising a method for producing any one of the prophylactic and therapeutic pharmaceutical composition It is about.

Hereinafter, the present invention will be described in detail.

leaven

The yeast of this invention should just be a yeast used as a foodstuff, The kind is not specifically limited. For example, yeast of the present invention is Saccharomyces cerevisiae, Saccharomyces carlsbergensis, Saccharomyces fermentati , Saccharomyces bayanus, Saccharomyces sake, Saccharomyces mandshuricus ,, Saccharomyces anamensis, Saccharomyces formosensis, this may be used, such as Saccharomyces ellipsoideus, Saccharomyces coreanus, preferably use Saccharomyces cerevisiae Can be.

Yeast hydrolyzate

The yeast hydrolyzate of the present invention is a hydrolyzate prepared by treating transglutaminase (TGase) in yeast. Preferably, the yeast hydrolyzate of the present invention is a yeast hydrolyzate prepared by complex treatment of yeast with flavozyme and transglutaminase, and more preferably by treating the flavozyme and transglutaminase sequentially It is a manufactured hydrolyzate. That is, most preferably, the yeast hydrolyzate of the present invention is prepared by hydrolyzing yeast with flavozyme and then hydrolyzing it with transglutaminase.

Appetite Suppression

In the present invention, appetite suppression means suppressing the desire to eat food, that is, appetite is generated.

Appetite Suppression Composition

The appetite suppressing composition of the present invention inhibits the expression of NPY (neuropeptide Y) and promotes the expression of cocaine- and amphetamine-related transcript (CART). In addition, the appetite suppressing composition of the present invention increases the secretion of satiety hormones such as leptin and reduces the secretion of fasting hormones such as ghrelin. As a result, the appetite suppressing composition of the present invention suppresses appetite and suppresses dietary intake.

The composition of the present invention may be a food composition or a feed composition. In addition, the composition of the present invention can be administered with any one selected from the group consisting of atherosclerosis, visceral obesity, abdominal obesity, hyperlipidemia, fatty liver and obesity.

Food composition

The present invention provides a food composition comprising a yeast hydrolyzate as an active ingredient. The food is not limited to, but not limited to, health supplements, health functional foods, functional foods, exercise aids, and the like, but also includes the addition of the yeast hydrolyzate of the present invention to natural foods, processed foods, and general food materials.

The food composition including the yeast hydrolyzate of the present invention as an active ingredient may be added as it is or used with other food or food compositions, and may be suitably used according to a conventional method. The blending amount of the active ingredient can be suitably determined according to the purpose of its use (prevention, health or therapeutic treatment). In general, the yeast hydrolyzate of the present invention may be added in an amount of 0.01 to 70.00% by weight, preferably 0.01 to 30.00% by weight, more preferably 0.01 to 10.00% by weight of the raw material in the manufacture of food or beverage. It can be added in an amount of%. The effective dose of the yeast hydrolyzate of the food composition may be used in accordance with the effective dose of the pharmaceutical composition, but may be below the above range for long term intake for health and hygiene purposes or for health control purposes. However, since the active ingredient has no problem in terms of safety, it may be used in an amount above the above range.

 There is no particular limitation on the kind of the food. Food compositions comprising the yeast hydrolyzate as an active ingredient may be used in the form of oral preparations, such as tablets, hard or soft capsules, solutions, suspensions, and the like, these preparations are acceptable conventional carriers, for example In the case of oral preparations, excipients, binders, disintegrants, lubricants, solubilizers, suspending agents, preservatives or extenders may be used.

Examples of foods to which the yeast hydrolyzate can be added include meat, sausage, bread, chocolate, candy, snacks, confectionary, pizza, ramen, other noodles, gums, dairy products including ice cream, various soups, drinks, tea, Drink agents, alcoholic beverages, powder formulations and vitamin complexes, and the like, but are not limited to these kinds of foods.

Pharmaceutical composition

The pharmaceutical composition comprising the yeast hydrolyzate of the present invention as an active ingredient has any one prophylactic and therapeutic ability selected from the group consisting of atherosclerosis, visceral obesity, abdominal obesity, hyperlipidemia, fatty liver and obesity

A pharmaceutical composition comprising the yeast hydrolyzate of the present invention as an active ingredient may be administered orally or parenterally and may be used in the form of a general pharmaceutical preparation. The preferred pharmaceutical preparations are those for oral administration such as tablets, hard or soft capsules, liquids, suspensions, etc. These pharmaceutical preparations can be prepared in conventional pharmaceutically acceptable carriers, for example, as excipients for oral preparations, Binders, disintegrators, lubricants, solubilizers, suspending agents, preservatives or extenders.

The dosage of the pharmaceutical composition comprising the yeast hydrolyzate of the present invention as an active ingredient may be determined by a specialist depending on various factors such as the patient's condition, age, sex, and complications, but generally 0.1 mg per kg of adult. To 10 g, preferably 10 mg to 1 g. Also, the daily dosage of the pharmaceutical composition per unit dosage form, or a half, 1/3 or 1/4 dose thereof, may be contained, and may be administered 1 to 6 times per day. However, in the case of long-term intake for the purpose of health and hygiene or for the purpose of controlling health, the amount may be less than the above range, and the active ingredient may be used in an amount of more than the above range since there is no problem in terms of safety.

Further, according to the present invention,

Hydrolyzing the yeast to flavozyme;

Hydrolyzing the yeast flavozyme hydrolyzate with transglutaminase; and

Atherosclerosis, visceral obesity, abdominal obesity, hyperlipidemia, fatty liver and obesity comprising the step of obtaining the yeast transglutaminase hydrolyzate comprising a method for producing any one of the prophylactic and therapeutic pharmaceutical composition It is about.

Appetite Suppression Composition

The present invention relates to a composition for inhibiting appetite comprising a yeast hydrolyzate as an active ingredient. The yeast hydrolyzate may be prepared by hydrolyzing yeast with flavozyme and then hydrolyzing it with transglutaminase. In addition, the appetite suppressing composition may be a food composition or a feed composition. The composition for inhibiting appetite is a pharmaceutical composition for preventing and treating any one selected from the group consisting of arteriosclerosis, visceral obesity, abdominal obesity, hyperlipidemia, fatty liver and obesity, having an ability of inhibiting the expression of NPY or promoting the expression of CART. May also be used. In addition, the appetite suppressing composition may be administered with any one selected from the group consisting of atherosclerosis, visceral obesity, abdominal obesity, hyperlipidemia, fatty liver and obesity.

The present invention also relates to a method for producing an appetite suppressing composition comprising the step of hydrolyzing the yeast; and obtaining the yeast hydrolyzate. The yeast hydrolysis step may be carried out by hydrolyzing the yeast to flavozyme, and then hydrolyzing it with transglutaminase.

BRIEF DESCRIPTION OF THE DRAWINGS The advantages and features of the present invention, and the manner of achieving them, will be apparent from and elucidated with reference to the embodiments described hereinafter in conjunction with the accompanying drawings. It should be understood, however, that the invention is not limited to the disclosed embodiments, but is capable of many different forms and should not be construed as limited to the embodiments set forth herein. Rather, these embodiments are provided so that this disclosure will be thorough and complete, To fully disclose the scope of the invention to those skilled in the art, and the invention is only defined by the scope of the claims.

material

The protease KH-15 used in the present invention was obtained by using Bacillus sp. KH-15, which is isolated and preserved in the doenjang at the Department of Food and Nutrition, Korea University, as a production strain of protease (Korea Patent Registration) 10-0999429, etc.).

Preparation of Yeast Hydrolyzate (Examples and Comparative Examples)

Yeast hydrolyzate was produced in Salom Bio (Gunpo, Korea) according to the following method. Yeast hydrolyzate SCP-20 contains Saccharomyces cerevisiea IFO 2346 with 2% glucose, 0.6% (NH ₄ ) ₂ SO ₄ , 0.1% MgSO ₄ 7H ₂ O, 0.2% KH ₂ PO ₄ , 0.03% K ₂ HPO ₄ , 0.1% After incubation for 48 hours at 30 ° C using a medium consisting of NaCl, the cells were recovered by centrifugation at 3,000 × g. 50 mM phosphate buffer solution (pH 7.0) was added to the recovered cells 10 times of the cell weight, and Flavozyme (Novozymes Korea Limited, 1000 LAPU / g) was added to 0.5% of the cell weight to 6 at 30 ° C. Hydrolysis was carried out for a time. After 6 hours, incubated for 10 minutes in a 100 ° C water bath to inactivate the enzyme, the supernatant obtained by centrifugation at 8,000 × g was 10 kDa or less using an ultrafilter (Sartorius, Gottingen, Germany, 10 kDa cut-off). Was recovered and spray-dried to obtain a yeast flavozyme hydrolyzate, which was used as Comparative Example 1.

On the other hand, yeast was hydrolyzed in the same manner as in Comparative Example 1 except for using the protease KH-15 instead of flavozyme, to obtain a yeast KH-15 hydrolysate was used as Comparative Example 2 .

The spray-dried yeast flavozyme hydrolyzate (Comparative Example 1) was dissolved in distilled water to prepare a 10% yeast hydrolyzate, and a transglutaminase (TGase 1000) at a ratio of 200: 1 (w / w). unit / g, Ajinomoto, Tokyo, Japan) was added to the reaction at 38 ℃ 4 hours. After 4 hours, the enzyme was inactivated at 90 ° C. for 10 minutes to obtain a yeast TGase hydrolyzate, which was used in Example 1.

Experimental Example 1 Analysis of Yeast Hydrolyzate

The components of the previously prepared yeast hydrolysates were analyzed. As a result, the total nitrogen content of Comparative Example 1, Comparative Example 2 and Example 1 was 103.8 mg / g, 104.8 mg / g, 104.2 mg / g, respectively, there was no significant difference. The amino nitrogen amount (AN), which can indirectly determine the length of the peptide chain of the hydrolyzate, was 58.1 mg / g and 60.1 mg / g, respectively. 1 was 225.25 mg / g, indicating a slight decrease due to TGase treatment. This resulted in a decrease in the amount of amino nitrogen exposed to the end of the peptide as the length of the short chain peptide was increased by TGase treatment.

In addition, the surface hydrophobicity of the peptide was 251.2 and 261.2 in Comparative Example 1 and Comparative Example 2, but the hydrophobicity of Example 1 was reduced to 225.3. It is estimated that the amino acid involved in the hydrophobicity of the peptide surface was collected inward due to TGase treatment, and thus the hydrophobicity was changed (Table 1).

According to the above results, it was found that the TGase treatment converts the peptide chain to a slightly longer length than the yeast flavozyme hydrolyzate and KH-15 hydrolyzate.

Yeast hydrolyzate Total nitrogen
(mg / g) Amino nitrogen
(mg / g) Hydrophobicity of Peptides Comparative Example 1 103.8 ± 8.5 58.1 ± 4.9 251.2 ± 12.4 Comparative Example 2 104.8 ± 5.7 60.1 ± 3.7 261.2 ± 8.9 Example 1 104.2 ± 9.1 40.3 ± 6.7 225.3 ± 15.2

Experimental Example 2 Short-Term Appetite Suppression Test

Experimental animal

As an experimental animal, a male mouse of 7 weeks old of ICR was purchased from Samtako (Gyeonggi-do, Korea) and used. Experimental animals were bred at the temperature of 22 ± 2 ℃, relative humidity of 50 ± 10%, and 12 hours of contrast cycle in Korea University animal breeding room. Selected and used in the experiment.

Short term appetite suppression test

The experimental animals were divided into four groups, and mice were separated and bred according to the egg mass method. After 12 hours of fasting, saline, Comparative Example 1, Comparative Example 2, and Test Example 1 were injected intraperitoneally in an amount of 0.5 g / kg, respectively, and dietary intake and blood were collected at intervals of 0, 1, 2, 4, and 24 hours. The amount of leptin and ghrelin was measured. Specifically, at the end of the test, the animals were inhaled in anesthesia with ether, and blood was collected from the vein using a syringe (21G), centrifuged at 1,900 × g for 20 minutes, and serum was separated to obtain a sample for measuring leptin and ghrelin. Used. The levels of leptin and ghrelin were measured using an enzyme-linked immunosorbent assay (ELISA) kit (R & D Systems, Minneapolis, Minn., USA).

<2-1> Dietary Intake

A control group injected with physiological saline intraperitoneally after 12 hours of fasting in ICR mice (7 weeks old), and a group injected with yeast flavozyme hydrolyzate of 0.5 g / kg body weight (BW) intraperitoneally (Comparative Example) 1), 0.5 g / kg BW KH-15 yeast hydrolyzate was injected into the abdominal cavity (Comparative Example 2), yeast hydrolyzate was classified into Example 1 treated with TGase to observe dietary intake for 4 hours.

As a result, the yeast hydrolyzate group (Comparative Example 1, Comparative Example 2 and Example 1) was significantly lower in dietary intake than the control group (p <0.05) from 1 hour after the diet was provided to 4 hours observed. This resulted in a decrease in dietary intake as the amount of yeast hydrolyzate was administered in a dose-dependent manner, indicating an appetite suppression effect by the yeast hydrolyzate (FIG. 1).

<2-2> Appetite-related hormones in the blood

30 minutes after the administration of the sample, blood was collected and the hormones leptin and ghrelin related to appetite in the blood were analyzed. As a result, the satiety hormone leptin was a yeast hydrolyzate group of Comparative Examples 1, 2 and Example 1 in the control group. It showed a tendency to be secreted much compared, especially the amount of secretion of Example 1 was the most. On the other hand, the fasting hormone ghrelin was less secreted by the yeast hydrolyzate than the control group, in particular compared to Comparative Example 1 and Comparative Example 2 was measured that less secretion (Fig. 2). Therefore, the yeast hydrolyzate tends to induce appetite suppression, but the specific inhibitory effect was found to be excellent in Example 1.

According to the above results, the dietary intake of yeast hydrolyzate intraperitoneally decreased in Comparative Example 1, Comparative Example 2 and Example 1, and secreted a lot of leptin as a satiety hormone and less ghrelin as a fasting hormone in the blood. It was found to induce. In particular, Example 1 showed an excellent appetite suppression effect compared to Comparative Example 1 and Comparative Example 2.

Experimental Example 3 Long-term Appetite Suppression

Experimental animal

Male rats of SD 7-week-old were purchased from Samtaco (Gyeonggi-do, Korea) and used. Experimental animals were bred at the temperature of 22 ± 2 ℃, relative humidity of 50 ± 10%, and 12 hours contrast cycle in Korea University animal breeding room. Selected and used in the experiment.

Gene expression analysis

Hypothalamic gene expression was analyzed by real-time PCR. To summarize the process of RNA extraction, the hypothalamus tissue was added to 1 mL TRI-reagent (Sigma Chemical Co, Mo.) and homogenized using ultrasound. 200 μl of chloroform was added thereto, shaken vigorously for 15 seconds, and reacted at room temperature for 5 minutes, followed by centrifugation at 4 ° C. and 13,200 rpm for 15 minutes. The same volume of isoprophanol was added to the separated supernatant, reacted at room temperature for 10 minutes, and then centrifuged at 4 ° C. and 13,200 rpm for 10 minutes to precipitate RNA. Precipitated RNA was washed with 1 mL of cold 75% ethanol, centrifuged at 4, 13,200 rpm for 5 minutes, and the precipitate was dried at room temperature. Finally, the remaining RNA was dissolved in 30 μl of water without Rnase and stored at 70 ° C. RNA concentrations were measured at 260 and 280 nm wavelengths using Nano-drop.

To summarize the process of amplifying RNA, 1 ㎍ of isolated RNA was reacted for 5 minutes at 70 ℃, M-MuLV Reverse Transcriptase, dNTP, oligo (dT) primer (First Strand cDNA Synthesis Kit, Fermentas) 42 ℃ CDNA was made by reacting at 60 minutes for 10 minutes at 70 ° C. Then, FastStart Taq DNA plymerase (LightCycler FastStart DNA Master SYBR Green I, Roche), 3 mM MgCl2, 0.4 μM primers were added and amplified in LightCycler 1.5 Instrument. The process is followed by 10 minutes of pre-reaction at 95 ° C, followed by denaturation (95 ° C, 10 seconds), annealing (54-60 ° C, 5 seconds), and extension (72 ° C, 4-9 seconds). It was to repeat times. After completion of the reaction, to confirm the specificity of the amplification, the temperature was lowered to 65 ° C, and then gradually raised to a temperature of 95 ° C at a rate of 0.2 ° C / sec. Β-actin was used as the internal standard and the primer sequence is as follows. NPY5 is 5'-AAGCTCATTCCTCGCAGA-3 '(sense), 5'-GGGGGGAAACTAGGAAAA-3' (antisense), CART is 5'-CTCAAGAGTAAACGCATT-3 '(sense), 5'- ACAAGCACTTCAAGAGGAAA-3' (antisense), β- Actin was used as 5'-GTAACCAACTGGGACGAT-3 '(sense) and 5'-CTTGCTGATCCACATCTG-3' (antisense).

Long-term appetite suppression test

The experimental animals were divided into four groups, saline (control), Comparative Example 1, Comparative Example 2 and Test Example 1 were orally administered in an amount of 0.5 g / kg, respectively, and rats were separated and reared according to the egg mass method. Oral administration took place for 4 weeks, and diet and weight gain were measured at 2 day intervals.

After 4 weeks of infusion, 12 hours of fasting and anesthetized with Zoletil. The abdominal wall and chest wall are incised to expose the heart. A syringe is inserted into the left ventricle to collect blood, and 50 ml of cold saline is pushed through and perfused. Immediately before perfusion, the large venous sinus was dissected to induce perfusion fluid. Kim YW, Kim JY, Park YH, Park YH, Park SY, Won KC, Choi KH, Huh JY, Moon KH. (2006) Metformin Restores Leptin Sensitivity in High Fat Fed Obese Rats with Leptin Resistance The hypothalamus was extracted using the method of Diabetes 55: 716-724 and stored in liquid nitrogen for analysis. Extraction samples were used to measure the expression levels of neuropeptide Y (neuropeptide Y) (NPY) and anorexigenic neuropeptides (CART).

<3-1> Dietary Intake

Changes in dietary intake were measured during oral administration of yeast hydrolysates for 4 weeks. The dietary intake was 33.17 g / day in the saline-administered group, whereas the comparative yeast hydrolyzates of Comparative Example 1 and Comparative Example 2 were 31.92 and 30.81 g / day, respectively, and the yeast TGase hydrolyzate of Example 1 was 28.80 g / day. The dietary intake of day was shown. In Comparative Example 1, Comparative Example 2 and Example 1, the amount of dietary intake was all reduced, and in particular, the amount of dietary intake of Example 1 was found to be lower than that of other yeast hydrolysates (FIG. 3).

<3-2> weight gain

The change in body weight gain during oral administration of yeast hydrolyzate for 4 weeks was measured. Body weight increased over time, but there was a difference in increase between the experimental groups. In particular, when the 4-week experiment was completed, the control group, Comparative Example 1, Comparative Example 2 and Example 1 administration group showed an increase in weight gain of 219.8, 203.2, 204.5, 189.2 g, respectively. All of the yeast hydrolyzate administered groups showed a weight loss effect, and in particular, the administration group of Example 1 had a higher weight loss effect than Comparative Example 1 and Comparative Example 2 (FIG. 4).

<3-3> Changes in appetite-related neurotransmitters

Oral administration of yeast hydrolyzate was measured for the expression of appetite suppressant protein (CART) and appetite promoter protein (NPY). When the expression level of the appetite-stimulating protein (NPY) in the saline-administered group was 100%, NPY expression levels of 97.3%, 98.1% and 93.4% were shown in the administration groups of Comparative Example 1, Comparative Example 2 and Example 1, respectively. . Therefore, oral administration of yeast hydrolyzate decreased the expression level of NPY, a protein involved in appetite promotion, and in particular, Example 1 showed a significant decrease in the expression level of appetite promoter protein compared to Comparative Examples 1 and 2 (FIG. 5). (a)).

In addition, when the expression level of the CART, the appetite suppressing peptide, was 100%, the expression level of the control group in the saline-administered group was 136.3%, 139.6%, and 158.4% in the Comparative Example 1, Comparative Example 2, and Example 1 administration groups, respectively. Showed an increase. The CART expression level of the Comparative Example 1 and Comparative Example 2 administration group was higher than the control group, but the CART expression amount of the Example 1 administration group was higher than the Comparative Examples (Fig. 5 (b)).

That is, the oral administration group of Example 1 as well as Comparative Example 1 and Comparative Example 2 showed an increase in the expression of appetite suppressor protein CART and decreased appetite-promoting protein NPY expression, the effect of Example 1 compared to Comparative Examples 1 and 2 It was more effective.

Experimental Example 4 Sensory Evaluation

The yeast hydrolyzate of the said Comparative Example 1, Comparative Example 2, and Example was mixed with commercial yoghurt, and sensory evaluation was performed. 15 parts by weight of yeast hydrolyzate were added to 100 parts by weight of yogurt, and the panel was examined for taste, aroma and overall preference of 40 men and women aged 8 to 40 years.

As a result, the yeast hydrolyzate of Example 1 received excellent results in taste and overall preference, and there was no significant difference in flavor (Table 2).

flavor incense Overall preference Comparative Example 1 2.6 2.7 2.8 Comparative Example 2 2.4 3.0 2.5 Example 1 3.4 3.1 3.7

Claims (10)

The yeast hydrolyzate prepared by hydrolyzing the yeast to flavozyme and then hydrolyzing it with transglutaminase as an active ingredient,
The yeast is Saccharomyces cerevisiae,
The yeast hydrolyzate has a leptin secretion enhancing ability and cocaine- and amphetamine-related transcript expression promoting ability, the appetite suppression food composition for inducing appetite suppression and reduced dietary intake.
The method of claim 1,
Food composition for suppressing appetite characterized by having a neuropeptide Y expression suppression ability.
The yeast hydrolyzate prepared by hydrolyzing the yeast to flavozyme and then hydrolyzing it with transglutaminase as an active ingredient,
The yeast is Saccharomyces cerevisiae,
The yeast hydrolyzate has a leptin secretion enhancing ability and cocaine- and amphetamine-related transcript expression promoting ability, the appetite suppression feed composition for inducing appetite suppression and reduced dietary intake.
The method of claim 3, wherein
Feed composition for suppressing appetite, characterized by having a suppression of the expression of neuropeptide Y.
The yeast hydrolyzate prepared by hydrolyzing the yeast to flavozyme and then hydrolyzing it with transglutaminase as an active ingredient,
The yeast is Saccharomyces cerevisiae,
The yeast hydrolyzate has leptin secretion and cocaine- and amphetamine-related transcript expression promoting ability, induces appetite suppression and reduced dietary intake,
Pharmaceutical composition for the prevention and treatment of obesity.
6. The method of claim 5,
Pharmaceutical composition, characterized in that it has the ability to inhibit the expression of neuropeptide Y.
Hydrolyzing the yeast to flavozyme;
Hydrolyzing the yeast flavozyme hydrolyzate with transglutaminase; and
Obtaining the yeast transglutaminase hydrolyzate,
The yeast is Saccharomyces cerevisiae,
The yeast transglutaminase hydrolyzate has a leptin secretion enhancing ability and cocaine- and amphetamine-related transcript expression promoting ability, induces appetite suppression and reduced dietary intake, method of producing a food composition for suppressing appetite.
8. The method of claim 7,
The appetite suppressing food composition is characterized in that it has the ability to inhibit the expression of neuropeptide Y.
Hydrolyzing the yeast to flavozyme;
Hydrolyzing the yeast flavozyme hydrolyzate with transglutaminase; and
Obtaining the yeast transglutaminase hydrolyzate,
The yeast is Saccharomyces cerevisiae,
The yeast transglutaminase hydrolyzate has a leptin secretion enhancing ability and cocaine- and amphetamine-related transcript expression promoting ability, induces appetite suppression and reduced dietary intake, a method for producing a feed composition for suppressing appetite.
Hydrolyzing the yeast to flavozyme;
Hydrolyzing the yeast flavozyme hydrolyzate with transglutaminase; and
Obtaining the yeast transglutaminase hydrolyzate,
The yeast is Saccharomyces cerevisiae,
The yeast transglutaminase hydrolyzate has leptin secretion and cocaine- and amphetamine-related transcript expression promoting ability, induces appetite suppression and reduced dietary intake,
Method for preparing a pharmaceutical composition for the prevention and treatment of obesity.

Images